FLT3 and acute myeloid leukemia: The primary objectives of the study are (i) to assess the clinical efficacy of quizartinib in combination with high-dose cytarabine and mitoxantrone and (ii) to assess the clinical efficacy of MRD-triggered and preemptive quizartinib continuation therapy in patients with r/r- FLT3-ITD mutated AML.